Strategy for genetic testing in Charcot-Marie-disease
L J Miller1, A S D Saporta, S L Sottile
1Department of Neurology Wayne State University School of Medicine, 421 Ea Canfield, Elliman 3217, Detroit, MI 48201, USA.
Summary
This study developed algorithms to guide genetic testing for Charcot Marie Tooth disease (CMT) by analyzing patient data. These tools help identify specific CMT subtypes more efficiently, aiding diagnosis and research.
Area of Science:
- Neurology
- Genetics
- Medical Diagnostics
Background:
- Charcot Marie Tooth disease (CMT) affects 1 in 2500 individuals.
- Genetic testing for CMT is crucial for family planning, natural history studies, and clinical trial enrollment.
- Locus heterogeneity in CMT makes genetic cause identification complex and costly.
Purpose of the Study:
- To develop algorithms for directing genetic testing in Charcot Marie Tooth disease (CMT) patients.
- To identify distinguishing clinical and physiological features for various CMT subtypes.
- To simplify the diagnostic process for CMT.
Main Methods:
- Analysis of clinical phenotypes, neurophysiology, family history, and prevalence data from over 1000 CMT patients.
- Development of algorithms to correlate patient features with specific CMT subtypes.
- Utilizing motor nerve conduction velocities (MNCV) and developmental milestones (e.g., age of walking).
Main Results:
- Patients with slow upper extremity MNCV were predominantly diagnosed with CMT1A (88%).
- Intermediate MNCV was associated with CMT1X (52.8%) and CMT1B (27.8%).
- Very slow MNCV and delayed walking strongly indicated CMT1A (68%) or CMT1B (32%); CMT1B patients with very slow MNCV did not walk before 15 months. CMT2A was the most common axonal form.
Conclusions:
- Combining phenotypic and physiological data effectively identifies patients likely to have specific CMT subtypes.
- Algorithms were created to guide genetic testing strategies for CMT.
- These findings aid in more precise and efficient genetic diagnosis of Charcot Marie Tooth disease.
